- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd stock price live, this page displays NASDAQ ROIV stock exchange data. View the ROIV premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Roivant Sciences Ltd real time stock price chart below.
What Is the Roivant Sciences Ltd Stock Price Today?
The Roivant Sciences Ltd stock price today is 11.930.
What Is the Stock Symbol for Roivant Sciences Ltd?
The stock symbol for Roivant Sciences Ltd is ""ROIV.""
What Stock Exchange Does Roivant Sciences Ltd Trade On?
Roivant Sciences Ltd is listed and trades on the NASDAQ stock exchange.
Is Roivant Sciences Ltd a Good Stock to Buy?
Determining whether Roivant Sciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ROIV quote. (ISIN: BMG762791017)
What Is the Roivant Sciences Ltd Stock Price Today?
The Roivant Sciences Ltd stock price today is 11.930.
What Is the Stock Symbol for Roivant Sciences Ltd?
The stock symbol for Roivant Sciences Ltd is ""ROIV.""
What Stock Exchange Does Roivant Sciences Ltd Trade On?
Roivant Sciences Ltd is listed and trades on the NASDAQ stock exchange.
Is Roivant Sciences Ltd a Good Stock to Buy?
Determining whether Roivant Sciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ROIV quote. (ISIN: BMG762791017)
NASDAQ
Currency in USD
Fair Value
An estimate of a Roivant Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.850
12.028
52 wk Range
8.730
13.055
ROIV Scorecard
Full Analysis
Management has been aggressively buying back shares
ROIV is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Roivant Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.85012.028
52 wk Range
8.73013.055
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ROIV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Roivant Sciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
17.111
Upside
+43.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy
Roivant Sciences Ltd Company Profile
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Roivant Sciences Ltd Earnings Call Summary for Q1/2026
- Roivant Sciences reported Q1 2026 EPS of -$0.33, missing forecasts by 32%, with revenue of $2.17M, 71.78% below expectations
- Despite financial shortfall, stock rose 0.7% pre-market. Company maintains $4.5B cash balance and completed $1B share repurchase program
- Key upcoming catalysts include dermatomyositis trial data in H2 2025 and Graves' disease remission data in September
- CEO Matt Klein emphasized potential for significant commercial growth and practice-changing outcomes in Graves' disease treatment
- Company authorized additional $500M share repurchase, focusing on clinical execution and exploring global business development opportunities
Last Updated: 21/08/2025, 13:06
Read Full TranscriptCompare ROIV to Peers and Sector
Metrics to compare | ROIV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipROIVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.5x | −2.4x | −0.5x | |
PEG Ratio | 0.09 | −0.06 | 0.00 | |
Price/Book | 1.9x | 2.2x | 2.6x | |
Price / LTM Sales | 350.7x | 8.5x | 3.3x | |
Upside (Analyst Target) | 50.9% | 300.7% | 38.9% | |
Fair Value Upside | Unlock | 22.4% | 5.4% | Unlock |
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.111
(+43.43% Upside)
Earnings
Latest Release
Aug 11, 2025
EPS / Forecast
-0.33 / -0.25
Revenue / Forecast
2.17M / 7.69M
People Also Watch
FAQ
What Stock Exchange Does Roivant Sciences Trade On?
Roivant Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Roivant Sciences?
The stock symbol for Roivant Sciences is "ROIV."
What Is the Roivant Sciences Market Cap?
As of today, Roivant Sciences market cap is 8.15B.
What Is Roivant Sciences's Earnings Per Share (TTM)?
The Roivant Sciences EPS (TTM) is -1.09.
When Is the Next Roivant Sciences Earnings Date?
Roivant Sciences will release its next earnings report on 16 Nov 2025.
From a Technical Analysis Perspective, Is ROIV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Roivant Sciences Stock Split?
Roivant Sciences has split 0 times.
How Many Employees Does Roivant Sciences Have?
Roivant Sciences has 750 employees.
What is the current trading status of Roivant Sciences (ROIV)?
As of 30 Aug 2025, Roivant Sciences (ROIV) is trading at a price of 11.930, with a previous close of 11.94. The stock has fluctuated within a day range of 11.850 to 12.028, while its 52-week range spans from 8.730 to 13.055.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.